Biodesix
Biodesix's revenue rose 24.1% to $88 million in fiscal 2025. Its operating margin was −31.5%, up from −48.4% a year earlier. Free cash flow was −$24 million. The diluted share count rose 16.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Biodesix lost money in fiscal 2025: a net loss of $35 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 33 | 43 | 26 | 26 | 19 |
| Debt incl. finance leases | 10 | 30 | 40 | 40 | 50 |
| Net debt (negative means net cash) | −23 | −13 | 14 | 14 | 31 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.5x | 1.5x | — | 1.9x | — |
| Interest coverage | −9.1x | −6.3x | −4.3x | −4.2x | −3.6x |
| Current ratio | 1.5x | 2.3x | 1.2x | 2.8x | 1.9x |
| Quick ratio | 1.5x | 2.3x | 1.2x | 2.8x | 1.9x |
Cash flow
Projections
Project Biodesix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $3.1 million of Biodesix shares on the open market, and 5 insiders sold $104,401.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Jack W Schuler10% owner | Bought | 15,000 | $24.47 | $367,050 | Form 4 |
| Aug 11, 2026 | Jack W Schuler10% owner | Bought | 13,700 | $24.01 | $328,937 | Form 4 |
| Aug 10, 2026 | Jack W Schuler10% owner | Bought | 13,900 | $24.25 | $337,075 | Form 4 |
| Feb 23, 2026 | Scott HuttonPresident & CEO, Director | Sold | 1,490 | $12.78 | $19,042 | Form 4 |
| Feb 23, 2026 | Gary Anthony PestanoChief Development Officer | Sold | 556 | $12.78 | $7,106 | Form 4 |
| Feb 23, 2026 | Kieran O'KaneChief Commercial Officer | Sold | 535 | $12.78 | $6,837 | Form 4 |
| Feb 23, 2026 | Chris VazquezChief Accounting Officer | Sold | 211 | $12.78 | $2,697 | Form 4 |
| Feb 10, 2026 | Scott HuttonPresident & CEO, Director | Sold | 3,559 | $10.08 | $35,875 | Form 4 |
| Feb 10, 2026 | Robin Harper CowieCFO, Sec'y & Treasurer | Sold | 941 | $10.08 | $9,485 | Form 4 |
| Feb 10, 2026 | Kieran O'KaneChief Commercial Officer | Sold | 584 | $10.08 | $5,887 | Form 4 |
| Feb 10, 2026 | Gary Anthony PestanoChief Development Officer | Sold | 540 | $10.08 | $5,443 | Form 4 |
| Feb 10, 2026 | Chris VazquezChief Accounting Officer | Sold | 101 | $10.08 | $1,018 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 3 of 8 |
| Rule of 40 | −64.8% | −27.4% | −2.5% |
| Altman Z'' | −16.14 | −15.90 | −19.59 |
| Accruals ratio | −30.5% | 5.8% | −13.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 8 | 4 of 8 | 3 of 8 |
Compare
Put Biodesix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Biodesix | FY25 | 24.1% | −31.5% | −26.6% | −69.7% | — | 3 | |
| MDxHealth | FY25 | 19.8% | −13.4% | −3.1% | −41.8% | — | 3 | Compare |
| Exagen | FY25 | 19.6% | −21.1% | −21.4% | −115.0% | — | 3 | Compare |
| Ridgetech | FY26 | 10.2% | −1.4% | −1.1% | — | — | — | Compare |
| Grail | FY25 | 17.2% | −382.0% | −203.8% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 25 | 46 | 54 | 38 | 49 | 71 | 88 |
| Revenue growth | — | 85.5% | 19.6% | −29.9% | 28.5% | 45.3% | 24.1% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 10 | 11 | 13 | 13 | 10 | 10 | 12 |
| Operating income | −27 | −23 | −41 | −51 | −41 | −34 | −28 |
| Net income | −31 | −65 | −43 | −65 | −52 | −43 | −35 |
| Diluted EPS (US$) | −2,539.40 | −129.60 | −31.60 | −31.00 | −12.80 | −6.64 | −4.67 |
| Diluted shares (millions) | 0 | 0 | 1 | 2 | 4 | 6 | 8 |
| Cash flow | |||||||
| Cash from operations | −22 | −21 | −28 | −45 | −23 | −49 | −23 |
| Capital expenditure | 1 | 2 | 2 | 3 | 23 | 3 | 0 |
| Free cash flow | −23 | −23 | −30 | −48 | −46 | −52 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 4 | 5 | 6 | 5 | 7 | 4 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 5 | 62 | 33 | 43 | 26 | 26 | 19 |
| Debt incl. finance leases | 36 | 28 | 10 | 30 | 40 | 40 | 50 |
| Total assets | 45 | 121 | 76 | 93 | 99 | 97 | 88 |
| Total liabilities | 76 | 80 | 56 | 72 | 94 | 76 | 90 |
| Shareholders' equity | −225 | 41 | 20 | 21 | 5 | 21 | −2 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −108.9% | −50.3% | −75.1% | −132.4% | −84.2% | −48.4% | −31.5% |
| Net margin | −125.2% | −143.7% | −79.2% | −171.3% | −106.2% | −60.2% | −39.9% |
| Free cash flow margin | −93.8% | −51.2% | −55.9% | −126.3% | −93.3% | −72.7% | −26.6% |
| Rule of 40 (growth + FCF margin) | — | 34.4% | −36.2% | −156.2% | −64.8% | −27.4% | −2.5% |
| Return on capital | — | — | — | — | −251.1% | −102.8% | −69.7% |
| Return on equity | — | — | −141.8% | −324.5% | −414.1% | −337.3% | −383.1% |
| Return on assets | — | −78.8% | −43.8% | −77.5% | −54.3% | −43.7% | −38.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |